A deep understanding of physiology and experience attained with surgeons is helping us to design a new generation of minimally invasive prostheses aimed at mimicking human anatomy and restoring native physiology for critical functions.
Our approach heralds a new era for cardiovascular and urological therapies. The combination of our highly talented team and deep expertise will enable us to lead this major shift toward more physiological therapies.
Our minimally invasive implants undergo strict scientific and clinical testing in collaboration with top medical centers around the globe. We are also seeking to rein in healthcare expenditure, which represents a major challenge for public and private health systems alike.
Our implants are subject to rigorous scientific and clinical testing in collaboration with the most experienced medical centers in the world. We also aim to limit health spending, which is a real challenge for public and private health systems.
Patient health and unmet medical needs in structural heart disease, vascular therapy and urology are a daily concern for Affluent Medical. Millions of patients around the world are suffering and cannot always find optimal therapies and achieve a good quality of life with their poor prognosis. Our goal is to help patients worldwide to live longer healthier lives.
We believe that an alternative approach is possible that factors the capabilities of the human body and complex physiology into the design of products that reduce the risk of early or late disease recurrence.
We are committed to offering the best available therapies worldwide for hitherto largely unmet needs in terms of widespread and critical diseases.
Expertise and know-how
Affluent Medical strives to provide best-in-class minimally invasive implants. We leverage know-how concerning transcatheter and flow control technologies to achieve the following key benefits:
Mimicry of anatomy and restoration of physiology
Adjustability to meet individual patient needs
Minimally invasive implant procedures
Optimized and biocompatible components.
As a technology-focused company, we have developed a strong key intellectual property portfolio, and protected until 2041. All our breakthrough therapies have been published in scientific journals and presented at major medical conferences.
Approval from the Spanish and Italian competent authorities for the launch of the Minerva pilot clinical study in the centres of Murcia and Florence.
Management team strengthening with the arrival of Wenzel Hurtak as Vice President Operation for the Epygon Medical Device.
Affluent Medical’s capital strengthening with private placements worth €10.3 million and €4.1 million respectively.
Kephalios and Epygon receive €2.3 million in grants and repayable advances from THE PSPC Mivana project with the completion of new milestones.
Launch of the Minerva pilot clinical study of the Epygon medical device with the approval of the Austrian competent Authority.
Management team strengthening with the recruitment of Olivier Pierron as Chief Operating Officer and Jérôme Geoffroy as Chief Financial Officer.
First key stage of the PIAVE Artus project successfully completed with the payment to MyoPowers of grants and advances repayable by Bpifrance for an amount of €3.8 million.
Management team strengthening with the appointment of Michel Finance as CEO, and Professor François Laborde as Medical Director.
Positive results of the Scope clinical study validating the clinical benefit of embolization and genesis of Kardiozis technology.
Given their joint undertakings and the synergies that could potentially be generated, grouping of Epygon, Kardiozis, Kephalios and MyoPowers, to create Affluent Medical.
Formation of the Company and operation of contributions in kind of all the shares and convertible bonds issued by Epygon, Kephalios, Kardiozis and MyoPowers to the Company.
Transformation of the Company (incorporated as a simplified joint-stock company) into a public limited company with a Board of Directors on March 27, 2018.
Kalios and Artus enter into the clinical trial phase.
Receipt of the “innovative company” label from Bpifrance on April 25, 2018.
Entering into joint venture contracts between Shanghai Zuquan Investment Management Company Limited on one side and Epygon, Kephalios and MyoPowers on the other side.
Bpifrance assistance granted to MyoPowers for the “Artus” program.
Capital increase for MyoPowers for an amount of €4,500,000 subscribed mainly by funds generated by Truffle Capital and Novartis Bioventures Limited.
Entering into consortium agreement relating to the “Mivana” project “Innovative medical devices and techniques derived from the textile industry for the creation of a national cardiovascular sector” between Kephalios, Epygon, MDB Texinov and the Institut Français du Textile et de l’Habillement.
Capital increase for Kephalios by contribution of tangible and intangible assets relating to a development and marketing project of a medical device by Mitraflex at Kephalios.
Creation of MyoPowers, company specialized in the development of artificial muscles for the treatment of severe incontinence.
Capital increase for Epygon for an amount of €1,240,000 subscribed mainly by funds generated by Truffle Capital.
Kalios and Epygon enter into in-vivo preclinical phase (animal).
Creation of Epygon, company specialized in mitral valve replacement.
Creation of Kephalios, company specialized in minimally invasive correction of mitral regurgitation.
Creation of Kardiozis, company specialized in the long-term treatment of abdominal aortic aneurism.